Evidence Comparison
Survodutide and mazdutide are useful to compare because both target GLP-1 and glucagon receptors while following very different development paths. Survodutide remains investigational with a global obesity and MASH program; mazdutide has Phase 3 evidence and regulatory approval in China but is not FDA-approved in the United States.
Metabolic & Weight Loss
Investigational
Phase 3 investigational
Long-acting dual glucagon and GLP-1 receptor agonist.
Survodutide is a late-stage glucagon/GLP-1 dual agonist with published Phase 3 obesity evidence and a substantial liver-disease program, making it a useful comparator for both retatrutide and mazdutide.
Open metabolic pipeline record →Metabolic & Weight Loss
Not FDA-approved
Regulatory-grade / large Phase 3
Dual glucagon and GLP-1 receptor agonist.
Mazdutide and retatrutide both engage glucagon and GLP-1 pathways, but mazdutide is a dual agonist with a China-centered Phase 3 and approval history while retatrutide adds GIP and remains investigational.
Open metabolic pipeline record →Save this comparison
Keep the current two- or three-compound comparison for quick access in My Tools.
Loading comparison tool...
Regulatory status and evidence level are separate ideas. A compound can have meaningful human research and still remain investigational, while an FDA-approved product can have approval only for specific indications and formulations.
BACToBasics also separates direct human intervention evidence from animal, cell, endogenous-biology, or related-molecule evidence so weaker evidence does not inherit the certainty of stronger research.
This page is generated from the same structured evidence records as the main interactive compare tool. Updating a compound's regulatory status, evidence summary, safety context, or source list updates both experiences rather than maintaining separate copies.
Read the Research & Editorial Policy →Keep comparing
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
Compare mechanisms, evidence, regulatory status, safety context, and sources.
View comparison →
BACToBasics provides educational information only. Comparison pages are not medical advice, dosing advice, treatment guidance, anti-doping advice, or recommendations to use any compound.